In this sense, all the in silicoestimates of SCN9A overexpression with all clinically provenSNP markers of pain in PEPD, SFN, PE and CIP are consistentwith the manifestation of excessive SCN9A in patients withthese pathologies. This evidence concerns the gene SCN9A and hereditary sensory and autonomic neuropathy.